Zhenzhen Xun

This paper shows that combining IRE with anti-PD-1 induces abscopal effects in PDAC by triggering immune activation and systemic antitumor responses.

The paper identifies two resistance mechanisms in gastric cancer to chemo-immunotherapy, involving CEACAM5/6+ tumor cells and IL-1β+ macrophages, and suggests them as biomarkers and therapeutic targets.

This study identifies a co-evolved tumor-immune interaction involving KRAS signaling and LILRBhigh macrophages that drives PDAC recurrence and presents a therapeutic strategy targeting this axis.

This study identifies NRF2 pathway activation and SPP1⁺TREM2⁺ macrophages as drivers of chemoradiotherapy resistance in ESCC through multi-omics analysis of clinical trial data.

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.